Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | serous ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, RNAi, Western blot etc. |
| Sample | SOC tissues, cell lines (SK-OV-3, HO8910) |
| Expression Pattern | up-regulated |
| Function Description | We found that ANRIL levels were elevated in SOC tissues compared with normal controls and were highly correlated with advanced FIGO stage, high histological grade, lymph node metastasis, and poor prognosis. Functional studies suggest a critical role of ANRIL in the control of SOC cell migration/invasion at least in part through regulation of MET and MMP3. |
| Pubmed ID | 25845387 |
| Year | 2015 |
| Title | Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer. |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for serous ovarian cancer | OMIM COSMIC |